Vaginal Estrogen: The Treatment Too Many Women Are Never Offered
In my years of practice, I have watched women endure years of symptoms that are treatable — painful sex, persistent vaginal dryness, recurrent urinary tract infections, bladder urgency — without ever being told that an effective, well-studied, locally delivered treatment exists. That treatment is vaginal estrogen, and the gap between how well it works and how rarely it is discussed remains one of the more significant failures in women's healthcare.
This is not an emerging or experimental therapy. Vaginal estrogen has been studied for decades. Its safety and efficacy are well established in the medical literature. Major professional organizations — including The Menopause Society and the American Urological Association — endorse it as a first-line treatment for genitourinary syndrome of menopause. And yet a large proportion of women who would benefit from it have never had it offered, explained, or recommended.
The Menopause Society and the American Urological Association — endorse vaginal estrogen as a first-line treatment for genitourinary syndrome of menopause.
What Genitourinary Syndrome of Menopause Actually Is
Genitourinary syndrome of menopause, or GSM, is the umbrella term for the cluster of symptoms and tissue changes that occur in the vulva, vagina, urethra, and bladder as a result of declining estrogen. Unlike hot flashes, which often improve over time, GSM is progressive — it worsens without treatment, sometimes slowly, sometimes not.
The tissues of the vaginal walls, vulva, and urethra are profoundly estrogen-dependent. Estrogen maintains their thickness, elasticity, lubrication, pH balance, and nerve responsiveness. When estrogen declines, these tissues thin, lose moisture, become more fragile, and change in ways that affect daily comfort, sexual function, and urinary health.
Women describe this constellation of changes in strikingly consistent ways: a dryness that feels almost structural rather than just surface, a burning or irritation that is present even without any sexual activity, discomfort or pain with penetration that has developed where there was none before, a urine stream that feels more urgent, and UTIs that now seem to recur every few months without any obvious cause.
These are not vague complaints. They are predictable, physiological consequences of estrogen loss, and they are reversible with appropriate treatment.
What Vaginal Estrogen Is — and What It Is Not
Vaginal estrogen is a low-dose, locally delivered estrogen that works directly on the tissues of the vagina and urethra. It is available in several formulations: a cream, a tiny dissolvable tablet or suppository, and a flexible ring that sits in the vagina and releases a steady low dose over three months.
The key clinical fact that women are often not told: local vaginal estrogen produces minimal systemic absorption. The dose is a fraction of what systemic hormone therapy delivers, and it is designed to act locally on the target tissue rather than circulating throughout the body the way oral or transdermal systemic estrogen does.
This distinction matters enormously, because the primary reason women are not offered vaginal estrogen — or decline it when it is mentioned — is fear about estrogen and cancer risk. That fear, in the context of local vaginal estrogen at approved doses, is not supported by the evidence. Multiple major professional bodies, including The Menopause Society and the American College of Obstetricians and Gynecologists, have stated clearly that vaginal estrogen is appropriate and safe for the vast majority of women, including many breast cancer survivors, when prescribed appropriately.
The Specific Symptoms It Addresses
Vaginal dryness and irritation. Vaginal estrogen increases epithelial thickness, restores lubrication, and normalizes the vaginal pH that helps maintain the natural protective flora. Women who have been managing dryness with over-the-counter lubricants often describe the difference as fundamental — lubricants reduce friction at the surface, but they do not rebuild the tissue.
Painful sex (dyspareunia). Painful intercourse in menopause is most commonly caused by vulvovaginal atrophy — the thinning and fragility of genital tissue. Vaginal estrogen directly addresses this by restoring tissue integrity. Studies show significant reductions in dyspareunia with consistent use over weeks to months.
Recurrent urinary tract infections. This is one of the most underappreciated applications of vaginal estrogen. The urethra and bladder trigone are estrogen-sensitive, and their atrophy contributes directly to the recurrent UTIs that become far more common after menopause. Vaginal estrogen restores the local tissue environment in ways that reduce UTI frequency — and there is good clinical trial data supporting this.
Bladder urgency and urinary symptoms. Urethral tissue thinning contributes to urinary urgency, frequency, and stress leakage. Local estrogen can improve urethral closure pressure and reduce these symptoms, often meaningfully.
Clitoral and sexual responsiveness. The clitoris is estrogen-dependent tissue. Local estrogen therapy supports blood flow, nerve responsiveness, and tissue health in ways that can meaningfully improve arousal and orgasm — a dimension of this treatment's benefits that is almost never discussed.
Who Can Use It
The short answer: most women. The longer answer: the historically cautious guidance about estrogen use in women with a personal history of estrogen-receptor-positive breast cancer has been evolving. Multiple oncology and menopause societies have issued statements noting that, for women with significant quality-of-life impact from GSM, the risk-benefit discussion around local vaginal estrogen can be appropriate even in this population — ideally in shared decision-making involving the oncologist.
For women without that specific history, there are very few contraindications to vaginal estrogen. If you have been told you cannot use it without a clear, specific explanation grounded in your personal medical history, it is worth asking for that explanation — or seeking a second opinion from a menopause specialist.
How to Bring This Up With Your Provider
If vaginal estrogen has not been raised with you and you are experiencing symptoms of GSM, you do not need to wait for your provider to introduce it. You can raise it directly: "I've been experiencing vaginal dryness and discomfort that's affecting my daily life and my relationship. I've read about vaginal estrogen as a treatment for genitourinary syndrome of menopause. Is that something we should discuss for me?"
If your provider dismisses this without explanation, or tells you that you cannot use any estrogen without discussing your specific history in detail, it may be worth consulting with a clinician who has specific training in menopause medicine. These symptoms are treatable. You deserve a provider who will engage with that.
A Final Word on Normalizing This Conversation
Part of why vaginal estrogen remains underutilized is that the symptoms it treats are among the least discussed in women's healthcare. Discomfort with sex, vaginal dryness, and bladder urgency are still routinely dismissed as simply what getting older looks like. They are not. They are symptoms of a well-understood, well-treated medical condition — and the women who know that are the ones most likely to get the help they deserve.
Defy Menopause - Own the Change
Many women tell me: "One day I feel amazing. The next, I can barely get out of bed. Is this normal?"
Yes, it is. And no, you don’t have to suffer through it alone.
Hormonal fluctuations during perimenopause can make you feel like you’ve lost control of your body. But knowledge is powerful. And there are clear, science-backed ways to support your hormones, ease symptoms, and reclaim your energy.
That’s exactly why I created Defy Menopause: Own the Change — a 30-day program designed to give you the tools, knowledge, and support you need to move through these changes with clarity and confidence.
Inside, you’ll find:
Access to Dr. Tracy Verrico at one (1) live, group session
Clear action steps for managing symptoms naturally
Because you deserve more than just "putting up with it."
You deserve to thrive.
Let’s Connect
Schedule an Appointment | LinkedIn | YouTube | Instagram | Bona Dea Gynecology
Medical Disclaimer: The information provided in this blog is for general educational and informational purposes only and is not intended as, nor should it be considered, medical advice. This content does not establish a physician-patient relationship and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read in this newsletter. If you think you may have a medical emergency, call your doctor or emergency services immediately.
References
1. The Menopause Society (formerly NAMS). Genitourinary Syndrome of Menopause (GSM): Position Statement. menopause.org
2. Crean-Tate KK, Faubion SS, Pederson HJ, Vencill JA, Batur P. Management of genitourinary syndrome of menopause in female cancer patients and survivors. Am J Obstet Gynecol. 2020;222(2):103-113.
3. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-1068.
4. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016.
5. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11):753-756.
6. American Urological Association. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. 2022. auanet.org
7. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014.
